Stockreport

UNITY Biotechnology Reports Promising Topline Data from Phase 1 First-in-human Study of UBX0101 in Patients with Osteoarthritis of the Knee

Unity Biotechnology, Inc.  (UBX) 
Last unity biotechnology, inc. earnings: 3/11 04:05 pm Check Earnings Report
PDF Clinical results support senescent cell elimination with UBX0101 as a potential treatment for osteoarthritis Topline results demonstrate a dose-dependent and clinically [Read more]